{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:52:39Z","timestamp":1742385159136},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Budd-Chiari syndrome (BCS) leads to the development of liver fibrosis in most of the cases. However, the mechanism of BCS-related liver fibrosis is unclear, and it may be largely different from that induced by chronic viral hepatitis. Hepatic stellate cell (HSC) and its specific marker CD248\/endosialin are known to play an important regulatory role in the development of liver fibrosis. Additionally, hypoxia microenvironment and hypoxia-inducible factor (HIF) are involved in the regulation of CD248\/endosialin. Therefore, we hypothesize that hypoxia microenvironment which develops due to BCS can regulate the expression of CD248\/endosialin in HSC via HIF signaling pathway, which then affects the function of HSC and development of liver fibrosis. To confirm the hypothesis, two major investigations are necessary: (1) in the BCS animal model and clinical studies, the relationship between the severity of liver fibrosis and the expression of HIF and CD248\/endosialin in HSC will be explored; and (2) in the <jats:italic>in vitro<\/jats:italic> cell system, the effect of hypoxic microenvironment, HIF-1\u03b1 or HIF-2\u03b1, on the expression of CD248\/endosialin in HSC will be explored. It will be important to elucidate whether HIF signaling pathway regulates the expression of CD248\/endosialin, thereby inducing the development of BCS-related liver fibrosis.<\/jats:p>","DOI":"10.2478\/jtim-2018-0018","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:32:05Z","timestamp":1530145925000},"page":"66-69","source":"Crossref","is-referenced-by-count":4,"title":["Hypoxia-inducible factor may induce the development of liver fibrosis in Budd\u2013Chiari syndrome by regulating CD248\/endosialin expression: A hypothesis"],"prefix":"10.2478","volume":"6","author":[{"given":"Ye","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Gastroenterology , General Hospital of Shenyang Military Area , Shenyang , Liaoning Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology , General Hospital of Shenyang Military Area , Shenyang , Liaoning Province , China"},{"name":"Yuebei People\u2019s Hospital , Shaoguan , Guangdong Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery , General Hospital of Shenyang Military Area , Shenyang , Liaoning Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"PhD","given":"Sijun","family":"Hu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi\u2019an , Shaanxi Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"MD","given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology , General Hospital of Shenyang Military Area , Shenyang , Liaoning Province , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"2023041806195849154_j_jtim-2018-0018_ref_001_w2aab3b7b8b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Valla DC. Primary Budd-Chiari syndrome. J Hepatol 2009; 50:195-203.","DOI":"10.1016\/j.jhep.2008.10.007"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_002_w2aab3b7b8b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 2010; 5:487-94.","DOI":"10.1007\/s11739-010-0413-6"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_003_w2aab3b7b8b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"Riva N, Ageno W. Approach to thrombosis at unusual sites: Splanchnic and cerebral vein thrombosis. Vasc Med 2017; 22:529-40.","DOI":"10.1177\/1358863X17734057"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_004_w2aab3b7b8b1b6b1ab1b5b4Aa","doi-asserted-by":"crossref","unstructured":"Almdal TP, Sorensen TI. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver. Hepatology 1991; 13:650-55.","DOI":"10.1002\/hep.1840130407"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_005_w2aab3b7b8b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"Valla DC. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004; 19:S204-11.","DOI":"10.1111\/j.1440-1746.2004.03642.x"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_006_w2aab3b7b8b1b6b1ab1b5b6Aa","doi-asserted-by":"crossref","unstructured":"Ki M, Choi HY, Kim KA, Kim BH, Jang ES, Jeong SH. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int 2016; 36:1067-73.","DOI":"10.1111\/liv.13008"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_007_w2aab3b7b8b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"Ageno W, Dentali F, Pomero F, Fenoglio L, Squizzato A, Pagani G, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thromb Haemost 2017; 117:794-800.","DOI":"10.1160\/TH16-10-0781"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_008_w2aab3b7b8b1b6b1ab1b5b8Aa","doi-asserted-by":"crossref","unstructured":"Rajani R, Melin T, Bjornsson E, Broome U, Sangfelt P, Danielsson A, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival-an 18-year experience. Liver Int 2009; 29:253-9.","DOI":"10.1111\/j.1478-3231.2008.01838.x"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_009_w2aab3b7b8b1b6b1ab1b5b9Aa","doi-asserted-by":"crossref","unstructured":"Okuda H, Yamagata H, Obata H, Iwata H, Sasaki R, Imai F, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995; 22:1-9.","DOI":"10.1016\/0168-8278(95)80252-5"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_010_w2aab3b7b8b1b6b1ab1b5c10Aa","unstructured":"Liu L, Qi XS, Zhao Y, Chen H, Meng XC, Han GH. Budd-Chiari syndrome: current perspectives and controversies. Eur Rev Med Pharmacol Sci 2016; 20:3273-81."},{"key":"2023041806195849154_j_jtim-2018-0018_ref_011_w2aab3b7b8b1b6b1ab1b5c11Aa","doi-asserted-by":"crossref","unstructured":"Mancuso A. An update on management of Budd-Chiari syndrome. Ann Hepatol 2014; 13:323-6.","DOI":"10.1016\/S1665-2681(19)30860-9"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_012_w2aab3b7b8b1b6b1ab1b5c12Aa","doi-asserted-by":"crossref","unstructured":"Ren W, Qi X, Jia J, Yang M, Han G. Prevalence of hepatocellular carcinoma in Chinese Budd-Chiari syndrome patients: an extended systematic review using Chinese-language databases. Eur J Gastroenterol Hepatol 2013; 25:1241-3.","DOI":"10.1097\/MEG.0b013e32836104a4"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_013_w2aab3b7b8b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol 2013; 25:830-41.","DOI":"10.1097\/MEG.0b013e32835eb8d4"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_014_w2aab3b7b8b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383:1749-61.","DOI":"10.1016\/S0140-6736(14)60121-5"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_015_w2aab3b7b8b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 1998; 27:488-96.","DOI":"10.1002\/hep.510270224"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_016_w2aab3b7b8b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A 1992; 89:10832-6.","DOI":"10.1073\/pnas.89.22.10832"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_017_w2aab3b7b8b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Kontsekova S, Polcicova K, Takacova M, Pastorekova S. Endosialin: molecular and functional links to tumor angiogenesis. Neoplasma 2016; 63:183-92.","DOI":"10.4149\/202_15090N474"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_018_w2aab3b7b8b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Diaz LA Jr, Coughlin CM, Weil SC, Fishel J, Gounder MM, Lawrence S, et al. A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res 2015; 21:1281-8.","DOI":"10.1158\/1078-0432.CCR-14-1829"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_019_w2aab3b7b8b1b6b1ab1b5c19Aa","doi-asserted-by":"crossref","unstructured":"Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall JL, Safran H, et al. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clin Cancer Res 2018, 24:316-25.","DOI":"10.1158\/1078-0432.CCR-17-1558"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_020_w2aab3b7b8b1b6b1ab1b5c20Aa","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo SP, Hamid OA, Tarhini A, Schadendorf D, Chmielowski B, Collichio FA, et al. A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Invest New Drugs 2018 36:103-13.","DOI":"10.1007\/s10637-017-0530-4"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_021_w2aab3b7b8b1b6b1ab1b5c21Aa","doi-asserted-by":"crossref","unstructured":"Mogler C, Wieland M, Konig C, Hu J, Runge A, Korn C, et al. Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage. EMBO Mol Med 2015; 7:332-8.","DOI":"10.15252\/emmm.201404246"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_022_w2aab3b7b8b1b6b1ab1b5c22Aa","doi-asserted-by":"crossref","unstructured":"Wilhelm A, Aldridge V, Haldar D, Naylor AJ, Weston CJ, Hedegaard D, et al. CD248\/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism. Gut 2016; 65:1175-85.","DOI":"10.1136\/gutjnl-2014-308325"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_023_w2aab3b7b8b1b6b1ab1b5c23Aa","doi-asserted-by":"crossref","unstructured":"Dhani N, Fyles A, Hedley D, Milosevic M. The clinical significance of hypoxia in human cancers. Semin Nucl Med 2015; 45:110-21.","DOI":"10.1053\/j.semnuclmed.2014.11.002"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_024_w2aab3b7b8b1b6b1ab1b5c24Aa","doi-asserted-by":"crossref","unstructured":"Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9Suppl 5:10-7.","DOI":"10.1634\/theoncologist.9-90005-10"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_025_w2aab3b7b8b1b6b1ab1b5c25Aa","doi-asserted-by":"crossref","unstructured":"Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26:225-39.","DOI":"10.1007\/s10555-007-9055-1"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_026_w2aab3b7b8b1b6b1ab1b5c26Aa","doi-asserted-by":"crossref","unstructured":"Zou D, Han T, Deng H, Shao X, Guo X, Qi X. Hypoxia-inducible factors in cancer: an overview of major findings from meta-analyses. AME Med J 2017; 2:48.","DOI":"10.21037\/amj.2017.04.08"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_027_w2aab3b7b8b1b6b1ab1b5c27Aa","doi-asserted-by":"crossref","unstructured":"Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol 2014; 61:1397-406.","DOI":"10.1016\/j.jhep.2014.08.025"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_028_w2aab3b7b8b1b6b1ab1b5c28Aa","doi-asserted-by":"crossref","unstructured":"Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl) 2016; 94:613-27.","DOI":"10.1007\/s00109-016-1408-1"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_029_w2aab3b7b8b1b6b1ab1b5c29Aa","doi-asserted-by":"crossref","unstructured":"Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002; 35:1010-21.","DOI":"10.1053\/jhep.2002.32524"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_030_w2aab3b7b8b1b6b1ab1b5c30Aa","doi-asserted-by":"crossref","unstructured":"Moon JO, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol 2009; 296:G582-92.","DOI":"10.1152\/ajpgi.90368.2008"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_031_w2aab3b7b8b1b6b1ab1b5c31Aa","doi-asserted-by":"crossref","unstructured":"Copple BL, Kaska S, Wentling C. Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice. J Pharmacol Exp Ther 2012; 341:307-16.","DOI":"10.1124\/jpet.111.189340"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_032_w2aab3b7b8b1b6b1ab1b5c32Aa","doi-asserted-by":"crossref","unstructured":"Roychowdhury S, Chiang DJ, McMullen MR, Nagy LE. Moderate, chronic ethanol feeding exacerbates carbon-tetrachloride-inducedhepatic fibrosis via hepatocyte-specific hypoxia inducible factor 1a. Pharmacol Res Perspect 2014; 2:e00061.","DOI":"10.1002\/prp2.61"},{"key":"2023041806195849154_j_jtim-2018-0018_ref_033_w2aab3b7b8b1b6b1ab1b5c33Aa","doi-asserted-by":"crossref","unstructured":"Ohradanova A, Gradin K, Barathova M, Zatovicova M, Holotnakova T, Kopacek J, et al. Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. Br J Cancer 2008; 99:1348-56.","DOI":"10.1038\/sj.bjc.6604685"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/jtim\/6\/2\/article-p66.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/pdf\/10.2478\/jtim-2018-0018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T11:02:20Z","timestamp":1681815740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.2478\/jtim-2018-0018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6,26]]},"published-print":{"date-parts":[[2018,6,26]]}},"alternative-id":["10.2478\/jtim-2018-0018"],"URL":"https:\/\/doi.org\/10.2478\/jtim-2018-0018","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}